In a prospective study by Alves et al., 2022 [125], of a total of 64 breast cancer patients, the plasma levels of inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-10 and tumor necrosis factor (TNF) were assessed in response to doxorubicin therapy. The gene discussed is IL6; the disease is breast carcinoma.